Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis
Randomized Trial Comparing Endoscopic Ultrasound-guided Radiofrequency Ablation vs.Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Alleviation of Abdominal Pain in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Center for Interventional Endoscopy - Florida Hospital
mi
from
Orlando, FL
Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis
Randomized Trial Comparing Endoscopic Ultrasound-guided Radiofrequency Ablation vs.Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Alleviation of Abdominal Pain in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Center for Interventional Endoscopy - Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Comparison Of Radiation Exposure To Patients During Endoscopic Retrograde Cholangiopancreatography (ERCP) Performed By Endoscopists Trained In Judicious Use Of Fluoroscopy With Those Without Formal Training
Comparison Of Radiation Exposure To Patients During ERCPs Performed By Endoscopists Trained In Judicious Use Of Fluoroscopy With Those Without Formal Training
Status: Enrolling
Updated:  12/31/1969
Memorial Hermann Hospital
mi
from
Houston, TX
Comparison Of Radiation Exposure To Patients During Endoscopic Retrograde Cholangiopancreatography (ERCP) Performed By Endoscopists Trained In Judicious Use Of Fluoroscopy With Those Without Formal Training
Comparison Of Radiation Exposure To Patients During ERCPs Performed By Endoscopists Trained In Judicious Use Of Fluoroscopy With Those Without Formal Training
Status: Enrolling
Updated: 12/31/1969
Memorial Hermann Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
On-site Cytopathology EUS-FNA
The Clinical Impact of Immediate On-site Cytopathology Evaluation During Endoscopic Ultrasound-Guided Fine Needle Aspiration of Pancreatic Mass: A Multicenter, Prospective Randomized Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
On-site Cytopathology EUS-FNA
The Clinical Impact of Immediate On-site Cytopathology Evaluation During Endoscopic Ultrasound-Guided Fine Needle Aspiration of Pancreatic Mass: A Multicenter, Prospective Randomized Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Albert Einstein Comprehensive Cancer Center
mi
from
Bronx, NY
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Albert Einstein Comprehensive Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
A Feasibility Study for Individualized Treatment of Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
A Feasibility Study for Individualized Treatment of Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
Treatment of Advanced Pancreatic Cancer With Opioid Growth Factor (OGF): Phase II
Status: Enrolling
Updated:  12/31/1969
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
Treatment of Advanced Pancreatic Cancer With Opioid Growth Factor (OGF): Phase II
Status: Enrolling
Updated: 12/31/1969
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
OGF & Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital and Health Network
mi
from
Allentown, PA
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
OGF & Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital and Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
OGF & Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study
Status: Enrolling
Updated:  12/31/1969
Penn State Hershey Medical Center
mi
from
Hershey, PA
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
OGF & Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study
Status: Enrolling
Updated: 12/31/1969
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Survivorship Promotion In Reducing IGF-1 Trial
Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins ProHealth
mi
from
Baltimore, MD
Survivorship Promotion In Reducing IGF-1 Trial
Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins ProHealth
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer
Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Fort Smith, AR
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Atlanta Regional
mi
from
Atlanta, GA
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Atlanta Regional
mi
from
Atlanta, GA
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Wichita
mi
from
Wichita, KA
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Kansas City
mi
from
Kansas City, MO
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Dayton
mi
from
Dayton, OH
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
All Saints Cancer Center at All Saints Healthcare
mi
from
Racine, WI
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
All Saints Cancer Center at All Saints Healthcare
mi
from
Racine, WI
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Eastern Connecticut Hematology and Oncology (ECHO)
mi
from
Norwich, CT
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Eastern Connecticut Hematology and Oncology (ECHO)
mi
from
Norwich, CT
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
MD Anderson
mi
from
Orlando, FL
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
MD Anderson
mi
from
Orlando, FL
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Berkshire Hematology Oncology, PC
mi
from
Pittsfield, MA
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Berkshire Hematology Oncology, PC
mi
from
Pittsfield, MA
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Metro MN CCOP
mi
from
Saint Louis Park, MN
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Metro MN CCOP
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Cancer Institute
mi
from
Kansas City, MO
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Cancer Institute
mi
from
Kansas City, MO
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Valley Hospital
mi
from
Paramus, NJ
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Valley Hospital
mi
from
Paramus, NJ
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Southeastern Medical Oncology Center
mi
from
Goldsboro, NC
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Southeastern Medical Oncology Center
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Teaching Hospital Brno-Bohunice
mi
from
Brno,
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Teaching Hospital Brno-Bohunice
mi
from
Brno,
Click here to add this to my saved trials
Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
A Phase I Dose-Escalating Study of Induction Gemcitabine/Pemetrexed Followed by Pemetrexed and Concurrent Upper Abdominal Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
A Phase I Dose-Escalating Study of Induction Gemcitabine/Pemetrexed Followed by Pemetrexed and Concurrent Upper Abdominal Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.
Pharmacokinetics, Biodistribution and Targeting of 111 In- Labeled Humanized PAM4IgG in Pre-Surgical Pancreatic Cancer Patients.An Examination of Protein Dose
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Institution, Dept of Radiology and Radiological Science
mi
from
Baltimore, MD
Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.
Pharmacokinetics, Biodistribution and Targeting of 111 In- Labeled Humanized PAM4IgG in Pre-Surgical Pancreatic Cancer Patients.An Examination of Protein Dose
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Institution, Dept of Radiology and Radiological Science
mi
from
Baltimore, MD
Click here to add this to my saved trials
SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary Pancreatic Cancer With Severe Obstructive Jaundice
Preoperative Endoscopic Biliary Drainage With Self Expanding Metal Stents (SEMS) vs. Direct Surgical Resection for Patients With Severe Obstructive Jaundice
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary Pancreatic Cancer With Severe Obstructive Jaundice
Preoperative Endoscopic Biliary Drainage With Self Expanding Metal Stents (SEMS) vs. Direct Surgical Resection for Patients With Severe Obstructive Jaundice
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer
Research Participation: Decision Making and Outcomes in Cancer Clinical Trials
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer
Research Participation: Decision Making and Outcomes in Cancer Clinical Trials
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.
Status: Enrolling
Updated:  7/2/2009
University of Colorado Denver
mi
from
Aurora, CO
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.
Status: Enrolling
Updated: 7/2/2009
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors
Investigating the Feasibility of Using Real-time Cine-MRI for Treating Moving and Deforming Tumors
Status: Enrolling
Updated:  6/24/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors
Investigating the Feasibility of Using Real-time Cine-MRI for Treating Moving and Deforming Tumors
Status: Enrolling
Updated: 6/24/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
Phase I/II Study of Preoperative Gemcitabine in Combination With Oral Hydroxychloroquine (GcHc) in Subjects With High Risk Stage IIb or III Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  1/11/2012
UPCI/UPMC Cancer Centers
mi
from
Pittsburgh, PA
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
Phase I/II Study of Preoperative Gemcitabine in Combination With Oral Hydroxychloroquine (GcHc) in Subjects With High Risk Stage IIb or III Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 1/11/2012
UPCI/UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection
MRI With Secretin Enhancement to Increase Conspicuity of Pancreatic Cancer
Status: Enrolling
Updated:  2/14/2012
Columbia University Medical Center
mi
from
New York, NY
Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection
MRI With Secretin Enhancement to Increase Conspicuity of Pancreatic Cancer
Status: Enrolling
Updated: 2/14/2012
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Detectable Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Status: Enrolling
Updated:  2/22/2012
Mayo Clinic
mi
from
Jacksonville, FL
Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Detectable Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Status: Enrolling
Updated: 2/22/2012
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
Status: Enrolling
Updated:  4/25/2012
Massachusetts General Hospital
mi
from
Boston, MA
Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
Status: Enrolling
Updated: 4/25/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Validation of a Mouse Model of Pancreatic Carcinogenesis
BRCA1 and BRCA2 Genetic Mutations in Mucinous Versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis
Status: Enrolling
Updated:  7/2/2012
Columbia University Medical Center
mi
from
New York, NY
Validation of a Mouse Model of Pancreatic Carcinogenesis
BRCA1 and BRCA2 Genetic Mutations in Mucinous Versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis
Status: Enrolling
Updated: 7/2/2012
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer
EUS Guided-Celiac Plexus Neurolysis (CPN) for Patients With Unresectable Pancreatic Cancer: A Multi-Center, Randomized, Single-Blinded Controlled Trial
Status: Enrolling
Updated:  8/28/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer
EUS Guided-Celiac Plexus Neurolysis (CPN) for Patients With Unresectable Pancreatic Cancer: A Multi-Center, Randomized, Single-Blinded Controlled Trial
Status: Enrolling
Updated: 8/28/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer
EUS Guided-Celiac Plexus Neurolysis (CPN) for Patients With Unresectable Pancreatic Cancer: A Multi-Center, Randomized, Single-Blinded Controlled Trial
Status: Enrolling
Updated:  8/28/2012
Florida Hospital
mi
from
Orlando, FL
Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer
EUS Guided-Celiac Plexus Neurolysis (CPN) for Patients With Unresectable Pancreatic Cancer: A Multi-Center, Randomized, Single-Blinded Controlled Trial
Status: Enrolling
Updated: 8/28/2012
Florida Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
Phase I Study of Combination of SOM 230 Long Acting Release (LAR) + Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  9/11/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
Phase I Study of Combination of SOM 230 Long Acting Release (LAR) + Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 9/11/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials